Actualizado 02/09/2012 17:02 CET
- Comunicado -

Un informe destaca la importancia de reducir el riesgo en el tratamiento de la COPD (y 2)


1) Global Strategy for the Diagnosis, Management and Prevention of COPD,
Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011.
http://www.goldcopd.org (acceso en julio de 2012).
2) Bateman ED, Rabe KF, Calverley PM, et al. Roflumilast with long-acting beta
2-agonists for COPD: influence of exacerbation history, Eur Respir J 2011;38:553-560.
3) Fabbri LM, et al. Effects of roflumilast in highly symptomatic COPD patients
[abstract]. En: European Respiratory Society's 22nd Annual Congress; 2012 Del 1 al 5
de septiembre; Viena, Austria: ERS; 2012. Abstracto P742.
4) World Health Organization. COPD. Fact Sheet No 315. 2008.
http://www.who.int/mediacentre/factsheets/fs315/en/index.htm... (acceso en junio de
2012)
5) Seemungal TAR, Donaldson GC, Paul EA,Bestall JC, Jeffries DJ, Wedzicha JA.
Effect of exacerbation on quality of life in patients with chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-1422
6) Hatzelmann A, et al. The preclinical pharmacology of roflumilast - a
selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive
pulmonary disease, Pulm Pharm Ther 2010;23:235-256.
7) Calverley PMA, et al. Roflumilast in symptomatic chronic obstructive
pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685-94.
8) Fabbri LM, et al. Roflumilast in moderate-to-severe chronic obstructive
pulmonary disease treated with long-acting bronchodilators: two randomised clinical
trials. Lancet 2009;374:695-703.
9) Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the
treatment of chronic obstructive pulmonary disease. Br J Pharm 2011;163:53-67.
10) EU Summary of Product Characteristics, Daxas(R), Mayo de 2011 (disponible en
http://www.ema.europa.eu)

Este comunicado se ha emitido por medio de Takeda Pharmaceuticals International GmbH, Thurgauerstrasse 130, CH-8152 Glattpark-Opfikon (Zurich), Suiza

[TAB]

Video:

http://www.multivu.com/mnr/56582-expert-report-on-copd-launc...

[FTAB]

CONTACTO: Contacto: Fleishman-Hillard, Cheryl Pitcher, Tel:+44(0)7809-492191, Email: Cheryl.Pitcher@fleishmaneurope.com; TakedaPharmaceuticals International GmbH, Tobias Cottmann, Tel: +41-79-2177252


Video:
http://www.multivu.com/mnr/56582-expert-report-on-copd-launc...

CONTACTO: Contacto: Fleishman-Hillard, Cheryl Pitcher, Tel:+44(0)7809-492191, Email: Cheryl.Pitcher@fleishmaneurope.com; TakedaPharmaceuticals International GmbH, Tobias Cottmann, Tel: +41-79-2177252